Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Venetoclax phase III trial disappointment

Lawrence Boise • 12 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Dexamethasone Venetoclax
BELLINI

Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses surprising results from a phase III venetoclax combination therapy trial at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Lawrence Boise

Genomics & epigenomics in multiple myeloma: key updates and potential clinical applications 8:12
Genomics & epigenomics in multiple myeloma: key updates and potential clinical applications
Benjamin Barwick et al. • 12 Apr 2025
History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
The role of the tumor microenvironment in drug resistance in multiple myeloma 0:49
The role of the tumor microenvironment in drug resistance in multiple myeloma
Lawrence Boise • 28 Sep 2023
Ongoing research exploring mechanisms of resistance to IMiDs in myeloma 1:12
Ongoing research exploring mechanisms of resistance to IMiDs in myeloma
Lawrence Boise • 28 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals